599CC, Senior Scientist, Cancer Immunotherapy (T cell enhancement)

Job Code 599CC

Description

Fate Therapeutics is in search of a talented and motivated individual to become part of our T cell cancer immunotherapy team. Our rapidly growing team is part of a great effort to develop allogeneic, off-the-shelf adoptive cell therapy products. The successful candidate will be responsible to lead a research and development team for discovery of T cell enhancers to be expressed at unique temporal and spatial events to further enhance functional activity without eliciting exhaustion. Paramount to this position is the ability to work collaboratively with peers across multiple disciplines, both internally and with outside partners, including top pharmaceutical and academic labs, and to guide and coach others in a team environment. This position requires a strong background in T cell biology, cancer biology, and tumor immunology. This individual is expected to develop and lead colleagues and projects contributing to our T cell research and development team focusing on persistence, cytokine autonomy, and liquid and solid tumor targeting. As part of the team, the scientist will improve our understanding of iPSC-derived, engineered T cells through design, planning, and execution of in vitro and in vivo experiments. Collaboration with both external and internal partners places a high value on strong communication and professional skills is required. This is a full-time position reporting to a Principal Scientist, Cancer Immunotherapy and is located at our corporate headquarters in San Diego.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 599CC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.